{"id":64105,"date":"2026-04-28T11:02:00","date_gmt":"2026-04-28T03:02:00","guid":{"rendered":"https:\/\/flcube.com\/?p=64105"},"modified":"2026-04-28T11:02:01","modified_gmt":"2026-04-28T03:02:01","slug":"bio-thera-solutions-reports-25-84-revenue-growth-in-2025-driven-by-biosimilar-portfolio-expansion-and-us-market-entry","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64105","title":{"rendered":"Bio-Thera Solutions Reports 25.84% Revenue Growth in 2025 Driven by Biosimilar Portfolio Expansion and US Market Entry"},"content":{"rendered":"\n<p><strong>Bio-Thera Solutions Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688177:SHA\">SHA: 688177<\/a>) announced its financial results for fiscal year 2025, reporting revenues of <strong>RMB 935.22 million<\/strong> (approximately <strong>USD 136.92 million<\/strong>), representing a <strong>25.84% year-over-year increase<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-performance-summary\">Financial Performance Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>2025 Result<\/th><th>YoY Change<\/th><th>Primary Drivers<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenue<\/strong><\/td><td>RMB 935.22M (USD 136.92M)<\/td><td>+25.84%<\/td><td>Qletli &amp; Shiruili sales growth; Starjemza US launch<\/td><\/tr><tr><td><strong>Revenue Streams<\/strong><\/td><td>Sales + License Income<\/td><td>Expanded<\/td><td>Dual revenue model strengthening<\/td><\/tr><tr><td><strong>Market Coverage<\/strong><\/td><td>3,500+ hospitals; 2,500+ pharmacies<\/td><td>Continued expansion<\/td><td>Nationwide commercial network<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-portfolio-highlights\">Product Portfolio Highlights<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Qletli (adalimumab biosimilar)<\/strong>: Established product showing steady sales growth in Chinese market<\/li>\n\n\n\n<li><strong>Shiruili (tocilizumab biosimilar)<\/strong>: Contributing significantly to domestic revenue stream<\/li>\n\n\n\n<li><strong>Starjemza (ustekinumab biosimilar)<\/strong>: Recently launched in US market, creating new international revenue channel and licensing opportunities<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-infrastructure-development\">Commercial Infrastructure Development<\/h2>\n\n\n\n<p>During 2025, Bio-Thera implemented systematic enhancements to its marketing organization through refined management practices:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Team Structure<\/strong>: Optimized division of responsibilities among nationwide regional teams<\/li>\n\n\n\n<li><strong>Coordination<\/strong>: Enhanced cross-regional coordination mechanisms<\/li>\n\n\n\n<li><strong>Strategy Execution<\/strong>: Ensured precise implementation of sales strategies<\/li>\n\n\n\n<li><strong>Resource Allocation<\/strong>: Improved efficiency in market resource deployment<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-penetration-metrics\">Market Penetration Metrics<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Coverage Area<\/th><th>Status<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Geographic Reach<\/strong><\/td><td>Nationwide<\/td><td>All provinces, municipalities, and autonomous regions except Tibet, Hong Kong, Macao, and Taiwan<\/td><\/tr><tr><td><strong>Hospital Access<\/strong><\/td><td>3,500+<\/td><td>Prescribing hospitals across mainland China<\/td><\/tr><tr><td><strong>Pharmacy Distribution<\/strong><\/td><td>2,500+<\/td><td>Specialty and social pharmacies nationwide<\/td><\/tr><tr><td><strong>Growth Trajectory<\/strong><\/td><td>Expanding<\/td><td>Increasing both breadth and depth of market coverage<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-outlook\">Strategic Outlook<\/h2>\n\n\n\n<p>Bio-Thera&#8217;s dual-pronged strategy of strengthening its domestic commercial infrastructure while expanding internationally through biosimilar launches positions the company for continued growth. The successful US market entry with Starjemza establishes a precedent for future international expansion of its biosimilar portfolio, potentially creating additional licensing revenue streams beyond direct product sales.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding Bio-Thera Solutions&#8217; financial performance, market expansion, and commercial strategy. Actual results may differ due to risks including market competition, regulatory changes, and execution challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688177_20260428_N0PW.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688177_20260428_N0PW.\"><\/object><a id=\"wp-block-file--media-9fc890fe-0a5b-4e42-88bd-3ab503356883\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688177_20260428_N0PW.pdf\">688177_20260428_N0PW<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688177_20260428_N0PW.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-9fc890fe-0a5b-4e42-88bd-3ab503356883\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Bio-Thera Solutions Ltd. (SHA: 688177) announced its financial results for fiscal year 2025, reporting revenues&#8230;<\/p>\n","protected":false},"author":1,"featured_media":64107,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[289,1055],"class_list":["post-64105","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-bio-thera-solutions","tag-sha-688177"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bio-Thera Solutions Reports 25.84% Revenue Growth in 2025 Driven by Biosimilar Portfolio Expansion and US Market Entry - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Bio-Thera Solutions Ltd. (SHA: 688177) announced its financial results for fiscal year 2025, reporting revenues of RMB 935.22 million (approximately USD 136.92 million), representing a 25.84% year-over-year increase.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64105\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bio-Thera Solutions Reports 25.84% Revenue Growth in 2025 Driven by Biosimilar Portfolio Expansion and US Market Entry\" \/>\n<meta property=\"og:description\" content=\"Bio-Thera Solutions Ltd. (SHA: 688177) announced its financial results for fiscal year 2025, reporting revenues of RMB 935.22 million (approximately USD 136.92 million), representing a 25.84% year-over-year increase.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64105\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-28T03:02:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-28T03:02:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2801.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64105#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64105\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bio-Thera Solutions Reports 25.84% Revenue Growth in 2025 Driven by Biosimilar Portfolio Expansion and US Market Entry\",\"datePublished\":\"2026-04-28T03:02:00+00:00\",\"dateModified\":\"2026-04-28T03:02:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64105\"},\"wordCount\":306,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64105#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2801.webp\",\"keywords\":[\"Bio-Thera Solutions\",\"SHA: 688177\"],\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64105#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64105\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64105\",\"name\":\"Bio-Thera Solutions Reports 25.84% Revenue Growth in 2025 Driven by Biosimilar Portfolio Expansion and US Market Entry - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64105#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64105#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2801.webp\",\"datePublished\":\"2026-04-28T03:02:00+00:00\",\"dateModified\":\"2026-04-28T03:02:01+00:00\",\"description\":\"Bio-Thera Solutions Ltd. (SHA: 688177) announced its financial results for fiscal year 2025, reporting revenues of RMB 935.22 million (approximately USD 136.92 million), representing a 25.84% year-over-year increase.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64105#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64105\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64105#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2801.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2801.webp\",\"width\":1080,\"height\":608,\"caption\":\"Bio-Thera Solutions Reports 25.84% Revenue Growth in 2025 Driven by Biosimilar Portfolio Expansion and US Market Entry\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64105#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bio-Thera Solutions Reports 25.84% Revenue Growth in 2025 Driven by Biosimilar Portfolio Expansion and US Market Entry\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bio-Thera Solutions Reports 25.84% Revenue Growth in 2025 Driven by Biosimilar Portfolio Expansion and US Market Entry - Insight, China&#039;s Pharmaceutical Industry","description":"Bio-Thera Solutions Ltd. (SHA: 688177) announced its financial results for fiscal year 2025, reporting revenues of RMB 935.22 million (approximately USD 136.92 million), representing a 25.84% year-over-year increase.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64105","og_locale":"en_US","og_type":"article","og_title":"Bio-Thera Solutions Reports 25.84% Revenue Growth in 2025 Driven by Biosimilar Portfolio Expansion and US Market Entry","og_description":"Bio-Thera Solutions Ltd. (SHA: 688177) announced its financial results for fiscal year 2025, reporting revenues of RMB 935.22 million (approximately USD 136.92 million), representing a 25.84% year-over-year increase.","og_url":"https:\/\/flcube.com\/?p=64105","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-28T03:02:00+00:00","article_modified_time":"2026-04-28T03:02:01+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2801.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64105#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64105"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bio-Thera Solutions Reports 25.84% Revenue Growth in 2025 Driven by Biosimilar Portfolio Expansion and US Market Entry","datePublished":"2026-04-28T03:02:00+00:00","dateModified":"2026-04-28T03:02:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64105"},"wordCount":306,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=64105#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2801.webp","keywords":["Bio-Thera Solutions","SHA: 688177"],"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64105#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64105","url":"https:\/\/flcube.com\/?p=64105","name":"Bio-Thera Solutions Reports 25.84% Revenue Growth in 2025 Driven by Biosimilar Portfolio Expansion and US Market Entry - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=64105#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=64105#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2801.webp","datePublished":"2026-04-28T03:02:00+00:00","dateModified":"2026-04-28T03:02:01+00:00","description":"Bio-Thera Solutions Ltd. (SHA: 688177) announced its financial results for fiscal year 2025, reporting revenues of RMB 935.22 million (approximately USD 136.92 million), representing a 25.84% year-over-year increase.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64105#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64105"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=64105#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2801.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2801.webp","width":1080,"height":608,"caption":"Bio-Thera Solutions Reports 25.84% Revenue Growth in 2025 Driven by Biosimilar Portfolio Expansion and US Market Entry"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64105#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bio-Thera Solutions Reports 25.84% Revenue Growth in 2025 Driven by Biosimilar Portfolio Expansion and US Market Entry"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2801.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64105","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64105"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64105\/revisions"}],"predecessor-version":[{"id":64108,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64105\/revisions\/64108"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/64107"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64105"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64105"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64105"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}